Keith Thompson (CGT) announces the creation of Islexa

On day 1 of the World Stem Cells & Regenerative Medicine Congress, Keith Thompson, CEO of the Cell and Gene Therapy Catapult, announced, in partnership with the University of Aberdeen, the creation of a new company: Islexa. Islexa is developing an innovative method to produce laboratory grown islets, which are the organoids in charge of insulin production. This technology holds …

regenerative medicine

Guest Blog: “How to deliver the magic bullet in regenerative medicine”

One concept that worked well at for World Stem Cells & Regenerative Medicine Congress 2015 was the round table sessions. To be honest, I arrived a sceptic wondering how much more I would gain from the sessions, perhaps an hour sitting uncomfortably trying to engage in debate. The answer – a window into each company’s current work or the question …

diabetes, cognition, world drug safety congress americas, cambridge cognition

Whitepaper: Diabetes and Cognition

Disorder-specific impairments and treatment-induced effects on cognitive function Diabetes mellitus is defined by high blood glucose concentrations and the body’s inability to regulate these concentrations properly. The incidence and prevalence of diabetes vary across countries and are expected to increase during the coming decades owing to the influence of lifestyle and socioeconomic factors. The current prevalence of diabetes in Europe and …

AstraZeneca and Bristol-Myers Squibb Diabetes Alliance Provides $5 Million Grant for American Diabetes Association’s Pathway to Stop Diabetes Research Initiative

With diabetes projecting to hit more than half a billion of the population by Year 2035, there is an increasing need to look into diabetes management and personalized treatment. In view of this, AstraZeneca and BMS U.S Diabetes Alliance will be supporting the American Diabetes Association’s Pathway to stop Diabetes research program in a three-year grant.  The objective is to …

EMA not worried about pancreatitis risk with diabetes therapy

Last month we got concerned about the adverse effects of GLP-1 based diabetes drugs on the pancreas. The BMJ published an article suggesting that the link between the GLP-1 based diabetes drugs and pancreatitis and pancreatic cancer had been underplayed. The UK's Channel 4 then ran a Dispatches documentary on the issue. UK tabloids published headlines like "Is diabetes super …

Safety concerns put an end to Roche’s late-stage diabetes trial

Roche's phase III trial for diabetes candidate aleglitazar has been dogged by safety concerns, prompting the Swiss biotech to discontinue investigation of the drug. The AleCardio trial was evaluating the efficacy and safety of aleglitazar in patients with a recent acute coronary syndrome event and type 2 diabetes mellitus, but a review by the Data and Safety Monitoring Board (DSMB) …

GLP-1 diabetes drugs and pancreatic damage – has it been underplayed? BMJ, Channel 4 investigate

The timing could have almost been scripted. No sooner had an FDA panel downplayed historic safety fears over GSK's Avandia than a new diabetes drug safety scare has reared its head. A paper, published this morning in the British Medical Journal, details the results of a joint investigation between the BMJ and Channel 4 Dispatches into the potential proliferative or …

GSK’s Avandia: FDA panel recommend rosiglitazone restriction relaxation

An advisory committee to the US Food and Drug Administration (FDA) has voted to recommend market restrictions on former blockbuster drug rosiglitazone in the US. The GlaxoSmithKline drug, also known as Avandia, was once of the best-selling diabetes pill in the world, but became the centre of controversy as data emerged from the RECORD study linking the drug to cardiovascular …